Fluvoxamine Found Effective for Long COVID Fatigue

Fluvoxamine Found Effective for Long COVID Fatigue

Clinicians in India frequently encounter patients suffering from persistent exhaustion after a viral infection. Consequently, identifying effective treatments for this condition remains a top clinical priority. A recent study investigates the role of fluvoxamine for long COVID as a potential therapeutic solution for these patients. Researchers conducted an adaptive, randomized, placebo-controlled trial to evaluate its efficacy alongside metformin. Specifically, the trial enrolled 399 adults who experienced fatigue for at least 90 days after their initial infection.

Efficacy of Fluvoxamine for Long COVID

Participants received either fluvoxamine, metformin, or a placebo for a 60-day period. Furthermore, the team measured the primary outcome using the Fatigue Severity Scale (FSS). The results indicated that fluvoxamine significantly reduced fatigue levels by the end of the treatment period. However, metformin failed to demonstrate a significant benefit compared to the placebo group. In addition, patients treated with fluvoxamine reported substantial improvements in their overall quality of life. This positive effect persisted even 30 days after the treatment ended. Therefore, these findings provide a practical option for doctors managing post-viral exhaustion.

Clinical Safety and Fluvoxamine for Long COVID Usage

Safety data showed that fluvoxamine had a lower incidence of adverse events than metformin or placebo. Most side effects were mild, and severe complications remained rare across all study arms. Although the study has some limitations regarding long-term durability, the evidence is compelling. Doctors should consider these results when designing individualized care plans for long COVID patients. This study marks one of the first times a common medication has shown robust evidence in treating post-infectious fatigue.

Frequently Asked Questions

Q1: Does metformin help with long COVID fatigue?

No, the clinical trial showed that metformin did not significantly reduce fatigue compared to a placebo.

Q2: What was the dose of fluvoxamine used in the trial?

The participants took 100 mg of fluvoxamine twice daily for a total of 60 days.

References

1. Reis G et al. The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial. Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03959. PMID: 41911553.
2. World Health Organization. Post COVID-19 condition (Long COVID). 2024.
3. Ministry of Health and Family Welfare, India. National Comprehensive Guidelines for Management of Post-COVID Sequelae. 2021.